U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H19NO3
Molecular Weight 225.2842
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TERBUTALINE

SMILES

CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1

InChI

InChIKey=XWTYSIMOBUGWOL-UHFFFAOYSA-N
InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C12H19NO3
Molecular Weight 225.2842
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including

Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation. The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Terbutaline is used for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.

CNS Activity

CNS Active
4002
Curator's Comment: may cause some cardiostimulatory effects and CNS stimulation.

Originator

Approval Year

1974
167
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 3.16 µM [EC50]
Partial Agonist
297
 2.3 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8583
Terbutaline SULFATE

Approved Use

indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2706188/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERBUTALINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
148.6 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2706188/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERBUTALINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2706188/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERBUTALINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
Health Status: unhealthy
Age Group: 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Other AEs: Tachycardia, Systolic murmur...
Other AEs:
Tachycardia (1 patient)
Systolic murmur (1 patient)
Tremor (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
Health Status: pregnant
Age Group: 21 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Other AEs: Abdominal pain, Jitteriness...
Other AEs:
Abdominal pain (1 patient)
Jitteriness (1 patient)
Palpitations (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Other AEs: Nausea, Tachycardia...
Other AEs:
Nausea (1 patient)
Tachycardia (1 patient)
Tremor (1 patient)
Hyperglycemia (1 patient)
Hypokalemia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
2.5 mg single, subcutaneous
Overdose
Dose: 2.5 mg
Route: subcutaneous
Route: single
Dose: 2.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
pregnant, 35 years
Health Status: pregnant
Age Group: 35 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
Other AEs: Tachycardia...
Other AEs:
Tachycardia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
10 mg 3 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
unhealthy, 56 years (range: 44-68 years)
Health Status: unhealthy
Age Group: 56 years (range: 44-68 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
Other AEs: Tremor, Palpitation...
Other AEs:
Tremor
Palpitation
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
10 ug/kg single, intravenous
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
unhealthy, 9.1 years
Health Status: unhealthy
Age Group: 9.1 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
Other AEs: Cardiotoxicity...
Other AEs:
Cardiotoxicity (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
AEs

AEs

AESignificanceDosePopulation
Systolic murmur 1 patient
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
Health Status: unhealthy
Age Group: 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Tachycardia 1 patient
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
Health Status: unhealthy
Age Group: 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Tremor 1 patient
2 mg single, transdermal
Overdose
Dose: 2 mg
Route: transdermal
Route: single
Dose: 2 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
unhealthy, 15 years
Health Status: unhealthy
Age Group: 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/8400938
Abdominal pain 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
Health Status: pregnant
Age Group: 21 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Jitteriness 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
Health Status: pregnant
Age Group: 21 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Palpitations 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
pregnant, 21 years
Health Status: pregnant
Age Group: 21 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7793711
Hyperglycemia 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Hypokalemia 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Nausea 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Tachycardia 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Tremor 1 patient
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3692499
Tachycardia 1 patient
2.5 mg single, subcutaneous
Overdose
Dose: 2.5 mg
Route: subcutaneous
Route: single
Dose: 2.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
pregnant, 35 years
Health Status: pregnant
Age Group: 35 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/6102210
Palpitation
10 mg 3 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
unhealthy, 56 years (range: 44-68 years)
Health Status: unhealthy
Age Group: 56 years (range: 44-68 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
Tremor
10 mg 3 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
unhealthy, 56 years (range: 44-68 years)
Health Status: unhealthy
Age Group: 56 years (range: 44-68 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2806513
Cardiotoxicity 3 patients
10 ug/kg single, intravenous
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
unhealthy, 9.1 years
Health Status: unhealthy
Age Group: 9.1 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10891825
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Cav1.2
4
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Cav1.2
63
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9449
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9449
ChemicalBook
CB02131227
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02131227
eMolecules
27524076
https://www.emolecules.com/cgi-bin/more?vid=27524076
eMolecules
31228026
https://www.emolecules.com/cgi-bin/more?vid=31228026
MolPort
MolPort-003-850-418
https://www.molport.com/shop/molecule-link/MolPort-003-850-418
PubMed

PubMed

TitleDatePubMed
Beta-adrenoceptor-mediated cell signaling in the neonatal heart and liver: responses to terbutaline.
2001-12
Regulation of SP-B and SP-C secretion in rat type II cells in primary culture.
2001-12
Beta-adrenoceptor signaling in the developing brain: sensitization or desensitization in response to terbutaline.
2001-11-26
Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by beta-adrenergic agonist treatment.
2001-11
Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription.
2001-11
Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals.
2001-10-15
[Long-acting beta 2-stimulants].
2001-10
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].
2001-10
Perinatal factors associated with severe intracranial hemorrhage.
2001-10
Sulindac to prevent recurrent preterm labor: a randomized controlled trial.
2001-10
Fatal adverse drug events: the paradox of drug treatment.
2001-10
Regulation of fetal cardiac and hepatic beta-adrenoceptors and adenylyl cyclase signaling: terbutaline effects.
2001-10
Uterine contractility: vaginal administration of the beta-adrenergic agonist, terbutaline. Evidence of direct vagina-to-uterus transport.
2001-09
Fast enantiomeric separation of basis drugs by electrokinetic chromatography. Application to the quantitation of terbutaline in a pharmaceutical preparation.
2001-09
A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma.
2001-09
A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma.
2001-09
Off-label prescribing and the standard of care.
2001-08-20
Discriminative capacity of bronchodilator response measured with three different lung function techniques in asthmatic and healthy children aged 2 to 5 years.
2001-08-15
Beta1-adrenoceptor stimulation by high-dose terbutaline downregulates terbutaline-stimulated alveolar fluid clearance in ex vivo rat lung.
2001-08-02
Improved preparative-scale. continuous, free-flow electrophoretic separation of the enantiomers of terbutaline utilizing equal-but-opposite enantiomer mobilities.
2001-08
Pharmacological similarities and differences between beta2-agonists.
2001-08
Formoterol in clinical practice--safety issues.
2001-08
Formoterol used as needed--clinical effectiveness.
2001-08
Chiral separation of beta2-agonists by capillary electrophoresis using hydroxypropyl-alpha-cyclodextrin as a chiral selector.
2001-08
Antenatal terbutaline administration decreases the lung hyaluronan concentration in preterm rabbit pups.
2001-08
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists.
2001-08
Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes.
2001-07
The effect of the beta(2) adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function.
2001-07
Determination of the optical purity of (R)-terbutaline by 1H-NMR and RP-LC using chiral derivatizing agent, (S)-(-)-alpha-methylbenzyl isocyanate.
2001-07
Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions.
2001-06-22
The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).
2001-06-15
On-demand relief treatment for asthma.
2001-06-09
On-demand relief treatment for asthma.
2001-06-09
Adrenergic regulation of ion transport across adult alveolar epithelial cells: effects on Cl- channel activation and transport function in cultures with an apical air interface.
2001-06-01
Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis.
2001-06
Does the mode of inhalation affect the bronchodilator response in patients with severe COPD?
2001-06
Brittle asthma: a separate clinical phenotype of asthma?
2001-05-24
Comparison of the acute effects of salbutamol and terbutaline on heart rate variability in adult asthmatic patients.
2001-05
[Local necrosis of finger following stab with needle used to pump terbutaline sulfate (Bricalin)].
2001-05
Efficacy and safety of Ascoril in the management of cough--National Study Group report.
2001-02
Systemic capillary leak syndrome preceding plasma cell leukaemia.
2001
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001
Alveolar epithelial type II cell: defender of the alveolus revisited.
2001
An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder.
2001
Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate.
2001
Treatment of fetal congenital complete heart block with maternal administration of beta-sympathomimetics (terbutaline): a case report.
2001
Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids.
2001
Choices of therapy for exercise-induced asthma in children.
2001
Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease.
2001
Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
2001
Patents

Patents

JP2009526755A
475
JP2011510954A
147
JP4616993B2
12
JP4796732B2
9
JPH00597707A
9
JPH01197444A
15

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Asthma - Maintenance Tablets: 5 mg orally 3 times a day at 6 hour intervals during waking hours. May decrease to 2.5 mg/dose if side effects are pronounced. Do not exceed 15 mg in 24 hours. Inhalation aerosol: 2 inhalations separated by 60 seconds every 4 to 6 hours. Do not repeat more often than every 4 to 6 hours. Usual Adult Dose for Asthma - Acute Inhalation aerosol: 2 inhalations separated by 60 seconds every 4 to 6 hours. Do not repeat more often than every 4 to 6 hours. Subcutaneous Injection: 0.25 mg into the lateral deltoid area. A second 0.25 mg dose can be administered in 15 to 30 minutes if needed. Do not exceed 0.5 mg in 4 hours. Continuous intravenous infusion: 0.08 to 6 mcg/kg/min.
Route of Administration: Other
In Vitro Use Guide
Terbutaline elicited a relaxation response in isolated rat's tracheal smooth muscle at a dose of 10(-6) M or more
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:31:35 GMT 2025
Edited
by admin
on Mon Mar 31 18:31:35 GMT 2025
Record UNII
N8ONU3L3PG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASTHMASIAN
Preferred Name English
TERBUTALINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TERBUTALIN
Common Name English
(RS)-5-(2-(TERT-BUTYLAMINO)-1-HYDROXYETHYL)BENZENE-1,3-DIOL
Systematic Name English
TERBUTALINE [MI]
Common Name English
5-[2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol
Systematic Name English
5-[(1RS)-2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
Systematic Name English
BAMBUTEROL HYDROCHLORIDE IMPURITY A [EPIMPURITY]
Common Name English
1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-
Systematic Name English
TERBUTALINE [VANDF]
Common Name English
terbutaline [INN]
Common Name English
Terbutaline [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
WHO-ATC R03CC53
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
WHO-ATC R03CC03
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
WHO-ATC R03AC03
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
WHO-VATC QR03CC03
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
LIVERTOX 938
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
WHO-VATC QR03CC53
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
WHO-VATC QR03AC03
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
NCI_THESAURUS C319
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
Code System Code Type Description
CAS
23031-25-6
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
NCI_THESAURUS
C61965
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
IUPHAR
560
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
DRUG CENTRAL
2598
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
EVMPD
SUB10915MIG
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
ECHA (EC/EINECS)
245-385-8
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
INN
2616
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
SMS_ID
100000082686
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
LACTMED
Terbutaline
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
DAILYMED
N8ONU3L3PG
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
RXCUI
10368
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
TERBUTALINE
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
DRUG BANK
DB00871
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
CHEBI
9449
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
ChEMBL
CHEMBL1760
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
PUBCHEM
5403
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID7021310
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
FDA UNII
N8ONU3L3PG
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
MESH
D013726
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY
MERCK INDEX
m10572
Created by admin on Mon Mar 31 18:31:35 GMT 2025 , Edited by admin on Mon Mar 31 18:31:35 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of TERBUTALINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
BETA-2 ADRENERGIC RECEPTOR
TARGET -> AGONIST
Structure of TERBUTALINE SULFATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of IBUTEROL
PRODRUG -> METABOLITE ACTIVE
Structure of TERBUTALINE TRI-O-SULFATE
METABOLITE -> PARENT
MAJOR
URINE
Structure of TERBUTALINE 1,3-O-DISULFATE
METABOLITE -> PARENT
MAJOR
URINE
Structure of TERBUTALINE 1-SULFATE
METABOLITE -> PARENT
MAJOR
URINE
Structure of TERBUTALINE 3,5-O-DISULFATE
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
Structure of BAMBUTEROL HYDROCHLORIDE
PARENT -> IMPURITY
Related Record Type Details
Structure of TERBUTALINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966